Abstract
The following paper is an attempt to revise current data and the results of clinical trials concerning the impact of dapagliflozin on long-term cardiovascular complications of type 2 diabetes mellitus. Short-term clinical trials, including relatively small groups of patients, suggest positive influence of dapagliflozin on the cardiovascular system. Currently ongoing long-term trials are likely to confirm these data, but so far we can assume that dapagliflozin not only acts as an efficient antihyperglycaemic drug, but also protects the circulatory system in patients with type 2 diabetes mellitus.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call